LYRA Stock Price, Lyra Therapeutics Inc Quote, Chart

Market Summary

USD4.72-0.45

Market Closed

-8.70%

LYRA Stock Price

View Fullscreen

LYRA RSI Chart

LYRA Valuation

Market Cap

282.0M

Price/Earnings (Trailing)

-4.5

Price/Sales (Trailing)

180.99

EV/EBITDA

-4.17

Price/Free Cashflow

-4.38

LYRA Price/Sales (Trailing)

LYRA Profitability

EBT Margin

-4019.32%

Return on Equity

-70.1%

Return on Assets

-43.96%

Free Cashflow Yield

-22.82%

LYRA Fundamentals

LYRA Revenue

Revenue (TTM)

1.6M

Rev. Growth (Yr)

1.2K%

Rev. Growth (Qtr)

-73.16%

LYRA Earnings

Earnings (TTM)

-62.7M

Earnings Growth (Yr)

-6.47%

Earnings Growth (Qtr)

3.16%

Breaking Down LYRA Revenue

Last 7 days

-9.1%

Last 30 days

-27.7%

Last 90 days

-2.3%

Trailing 12 Months

91.9%

How does LYRA drawdown profile look like?

LYRA Financial Health

Current Ratio

5.35

LYRA Investor Care

Shares Dilution (1Y)

87.70%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.3M	1.2M	1.4M	1.6M
2022	554.5K	824.0K	1.1M	1.4M
2021	0	0	0	285.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lyra Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	waksal harlan	acquired	-	-	275,000	executive chair
Nov 10, 2023	waksal harlan	bought	74,095	2.9638	25,000	executive chair
May 31, 2023	nbvm gp, llc	bought	4,387,160	2.43	1,805,420	-
May 31, 2023	perceptive advisors llc	bought	9,000,000	2.4925	3,610,830	-
May 31, 2023	anderson edward t	bought	4,387,160	2.43	1,805,420	-
Jan 31, 2023	richard robert e.	acquired	-	-	30,000	svp, technical operations
Jan 31, 2023	noyes corinne	acquired	-	-	36,667	see remarks
Jun 10, 2022	merrifield c ann	bought	20,200	5.05	4,000	-
May 16, 2022	merrifield c ann	bought	1,640	5.00	328	-
May 13, 2022	merrifield c ann	bought	16,845	4.813	3,500	-

Which funds bought or sold LYRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Rosalind Advisors, Inc.	reduced	-39.4	-2,777,950	7,118,940	6.65%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-6,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-97,574	-	-%
Apr 25, 2024	Heritage Wealth Management, Inc./Texas	unchanged	-	9,800	62,200	0.04%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	new	-	259,000	259,000	-%
Apr 12, 2024	DLK Investment Management, LLC	unchanged	-	11,760	74,640	0.03%
Mar 11, 2024	VANGUARD GROUP INC	added	23.96	2,234,910	5,614,450	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	136,900	136,900	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	16,967,600	66,849,600	1.49%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-77,000	-	-%

Are Funds Buying or Selling LYRA?

Are funds buying LYRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LYRA

No. of Funds

Unveiling Lyra Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	pura vida investments, llc	3.06%	1,613,844	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	999%	5,553,552	SC 13G/A
Feb 14, 2024	citadel advisors llc	7.9%	6	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	8.9%	4,752,324	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	5.7%	3e+06	SC 13G/A
Feb 14, 2024	perceptive advisors llc	24.3%	12,757,563	SC 13D/A
Feb 13, 2024	vestal point capital, lp	5.7%	3e+06	SC 13G
Nov 16, 2023	point72 asset management, l.p.	5.4%	3e+06	SC 13G
Aug 25, 2023	samsara biocapital, l.p.	5.6%	2,780,261	SC 13G
Jun 12, 2023	citadel advisors llc	5.8%	6	SC 13G

Recent SEC filings of Lyra Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 01, 2024	EFFECT	EFFECT
Mar 22, 2024	10-K	Annual Report
Mar 22, 2024	S-3	S-3
Mar 22, 2024	S-8	Employee Benefits Plan
Mar 21, 2024	8-K	Current Report
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 01, 2024	8-K	Current Report

Peers (Alternatives to Lyra Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Lyra Therapeutics Inc News

Latest updates

Lyra Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-73.2%	146,000	544,000	458,000	410,000	11,000	359,000	525,000	468,000	-	-
Operating Expenses	-4.3%	16,623,000	17,371,000	16,961,000	17,723,000	15,166,000	15,185,000	14,925,000	12,393,000	13,909,000	11,095,000
S&GA Expenses	-12.9%	4,357,000	5,003,000	4,570,000	5,127,000	4,399,000	5,137,000	4,132,000	3,888,000	3,567,000	4,018,000
R&D Expenses	-0.8%	12,266,000	12,368,000	10,799,000	12,596,000	9,451,000	10,048,000	10,793,000	8,505,000	10,342,000	7,077,000
EBITDA Margin	7.1%	-40.00	-43.06	-48.49	-44.81	-39.73	-38.75	-51.30	-76.23	-149	-
Income Taxes	6.3%	17,000	16,000	12,000	14,000	-	-	-	-	-	-
Earnings Before Taxes	3.2%	-15,139,000	-15,635,000	-15,606,000	-16,241,000	-14,222,000	-14,766,000	-14,366,000	-11,911,000	-	-
EBT Margin	7.3%	-40.19	-43.36	-49.14	-45.67	-40.55	-39.79	-52.81	-78.47	-152	-
Net Income	3.2%	-15,156,000	-15,651,000	-15,618,000	-16,255,000	-14,235,000	-14,766,000	-14,366,000	-11,911,000	-13,615,000	-11,055,000
Net Income Margin	7.3%	-40.23	-43.40	-49.17	-45.69	-40.56	-49.99	-61.83	-85.88	-152	-
Free Cashflow	-39.2%	-19,845,000	-14,258,000	-14,353,000	-15,895,000	-12,192,000	-10,875,000	-8,484,000	-11,998,000	-12,380,000	-10,831,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	18.3%	143	121	126	94.00	110	119	130	47.00	55.00	68.00	76.00	73.00	81.00	87.00	93.00	41.00	15.00
Current Assets	-0.1%	105	105	118	85.00	101	112	122	41.00	48.00	61.00	70.00	67.00	76.00	84.00	89.00	36.00	10.00
Cash Equivalents	-10.0%	22.00	25.00	54.00	22.00	33.00	110	121	34.00	46.00	58.00	69.00	66.00	75.00	82.00	87.00	35.00	10.00
Net PPE	181.4%	2.00	1.00	1.00	2.00	2.00	4.00	4.00	4.00	5.00	5.00	4.00	3.00	2.00	1.00	0.00	0.00	0.00
Liabilities	46.4%	53.00	36.00	27.00	28.00	29.00	26.00	24.00	24.00	21.00	21.00	19.00	5.00	6.00	6.00	6.00	7.00	8.00
Current Liabilities	1.9%	20.00	19.00	14.00	14.00	14.00	14.00	11.00	22.00	18.00	18.00	6.00	4.00	5.00	5.00	4.00	5.00	5.00
Shareholder's Equity	6.2%	89.00	84.00	99.00	66.00	81.00	93.00	106	23.00	34.00	47.00	57.00	68.00	74.00	81.00	87.00	-	-
Retained Earnings	-5.1%	-311	-296	-280	-264	-248	-234	-219	-205	-193	-179	-168	-157	-149	-142	-136	-131	-127
Additional Paid-In Capital	5.3%	401	380	379	331	329	328	326	229	228	227	226	225	224	224	223	5.00	4.00
Shares Outstanding	15.5%	57.00	50.00	50.00	32.00	32.00	37.00	24.00	13.00	13.00	13.00	13.00	13.00	-	-	-	-	-
Float	-	-	-	143,246	-	-	-	102,993	-	-	-	-	-	-	-	53,323	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-35.0%	-19,058	-14,114	-14,282	-15,850	-12,164	-10,846	-8,470	-11,905	-11,297	-10,314	3,381	-7,590	-5,868	-3,780	-7,478	-4,017	-3,918	-3,827	-3,004	-3,005
Share Based Compensation	2.8%	1,482	1,441	1,354	1,610	1,757	1,739	1,107	844	782	733	656	599	592	468	619	134	103	49.00	44.00	48.00
Cashflow From Investing	84.3%	-2,359	-14,979	-561	5,315	-64,870	-29.00	-14.00	-93.00	-1,083	-517	-625	-1,160	-1,101	-589	-77.00	-8.00	-80.00	-10.00	-69.00	-52.00
Cashflow From Financing	4626.3%	18,920	-418	47,185	4.00	-	-236	96,487	6.00	-4.00	-84.00	185	262	7.00	-675	58,907	29,464	-	-	-	-

LYRA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 1,558	$ 1,363
Operating expenses:
Research and development	48,029	38,797
General and administrative	19,057	17,556
Loss on impairment of long-lived assets	1,592	1,316
Total operating expenses	68,678	57,669
Loss from operations	(67,120)	(56,306)
Other income:
Interest income	4,499	1,041
Total other income	4,499	1,041
Loss before income tax expense	(62,621)	(55,265)
Income tax expense	(59)	(13)
Net loss	(62,680)	(55,278)
Other comprehensive income:
Unrealized holding gain on short-term investments, net of tax	23	10
Comprehensive loss	$ (62,657)	$ (55,268)
Net loss per share -basic	$ (1.26)	$ (1.83)
Net loss per share -diluted	$ (1.26)	$ (1.83)
Weighted-average common shares outstanding-basic	49,804,283	30,235,689
Weighted-average common shares outstanding-diluted	49,804,283	30,235,689

LYRA Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,353	$ 32,550
Short-term investments	80,400	65,344
Prepaid expenses and other current assets	2,068	2,935
Total current assets	104,821	100,829
Property and equipment, net	2,043	2,243
Operating lease right-of-use assets	33,233	2,223
Restricted cash	1,392	1,392
Other assets	1,111	3,281
Total assets	142,600	109,968
Current liabilities:
Accounts payable	3,131	2,616
Accrued expenses and other current liabilities	9,374	9,030
Operating lease liabilities	5,434	1,549
Deferred revenue	1,658	1,275
Total current liabilities	19,597	14,470
Total operating lease liability, net of current portion	21,447	667
Deferred revenue, net of current portion	12,136	14,077
Total liabilities	53,180	29,214
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 57,214,550 and 31,827,659 shares issued and outstanding at December 31, 2023 and 2022, respectively	57	32
Additional paid-in capital	400,685	329,387
Accumulated other comprehensive income, net of tax	33	10
Accumulated deficit	(311,355)	(248,675)
Total stockholders’ equity	89,420	80,754
Total liabilities and stock and stockholders’ equity	$ 142,600	$ 109,968

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Maria Palasis Ph.D.
WEBSITE	https://lyratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	73

Lyra Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Lyra Therapeutics Inc? What does LYRA stand for in stocks?

LYRA is the stock ticker symbol of Lyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lyra Therapeutics Inc (LYRA)?

As of Fri Apr 26 2024, market cap of Lyra Therapeutics Inc is 281.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LYRA stock?

You can check LYRA's fair value in chart for subscribers.

What is the fair value of LYRA stock?

You can check LYRA's fair value in chart for subscribers. The fair value of Lyra Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lyra Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LYRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lyra Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LYRA is over valued or under valued. Whether Lyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYRA.

What is Lyra Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, LYRA's PE ratio (Price to Earnings) is -4.5 and Price to Sales (PS) ratio is 180.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYRA PE ratio will change depending on the future growth rate expectations of investors.